Navigation Links
Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Date:11/12/2009

BASKING RIDGE, N.J., Nov. 12 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, November 17 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. This conference is well attended and will include several hundred institutional investors with more than one hundred healthcare management teams presenting.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... 2014 Award winning unified communications ... four new-hosted collaboration bundles that combine next generation ... conferencing experiences for low, flat rate fees. ... businesses have optimized solutions to meet their technology ... audio only minutes (1K, 5K, 10K increments) or ...
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
(Date:10/1/2014)... LONDON, Sept. 30, 2014 This ... Enzymes in US$ Million by the following ... Specialty Enzymes. Specific end-use segments also analyzed ... The report provides separate comprehensive ... Asia-Pacific, Middle East, and Latin America. Annual ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... EDMONTON, Dec. 14 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), today,announced that following the ... the Company has received a recommendation to,continue MAESTRO-01, ... the treatment of secondary progressive multiple sclerosis., ...
... Company,(NYSE: LLY ) today announced that Robert Conley, ... Lilly Scholar focusing on schizophrenia,and other psychotic illnesses., ... our team here at,Lilly," said Jack Harris, M.D., vice ... clinician and scientist who brings,important experience to Lilly as ...
... Calif., Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ... has promoted B. Lynne Parshall, J.D. to Chief ... as Chief Financial,Officer, and is a Director of ... appropriately reflects the scope,of Lynne,s responsibilities at Isis," ...
Cached Biology Technology:BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3
(Date:9/30/2014)... the Ocean Health Index rates the Earth,s oceans ... In addition, for the first time, the report ... beyond national jurisdiction (high-seas areas) all critical ... and providing sustainable food sources. , In the ... led by scientists from UC Santa Barbara,s National ...
(Date:9/30/2014)... led by Clemson University associate professor Brian Powell, ... the U.S. Department of Energy,s Experimental Program to ... impact on South Carolina in the advancement of ... "Understanding the scientific and engineering needs for safely ... technologies is imperative if South Carolina is to ...
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... using a shotgun to kill a housefly is that even ... of damage to your home in the process. Hence the ... long faced a similar situation in chemotherapy: how to get ... "spillover" of the medication adversely affecting the healthy cells in ...
... . Gaza/Leipzig. Palestinian and German scientists ... that they take immediate measures to combat excessive nitrate ... their water samples were found to contain nitrate concentrations ... the limit recommended by the World Health Organization (WHO), ...
... scientist emeritus of the Smithsonian Tropical Research Institute ... the Aug. 12 issue of the journal ... that the following steps, if taken immediately, could ... reserves, enforce fishing regulations, implement aquaculture, remove subsidies ...
Cached Biology News:Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice 2Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice 3Drinking water in Gaza Strip contaminated with high levels of nitrate 2A recipe for saving the world's oceans from an extinction crisis 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... mutS are mismatch repair minus strains of ... repair of the newly synthesized unmethylated strand ... making them helpful in such systems as ... Systems. Both ES1301 and BMH 71-18 mutS ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: